ResearchMoz

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

GBI Research
Published Date » 2014-03-07
No. Of Pages » 109
   
 GBI Research, the leading business intelligence provider, has released its latest research: ‘NSCLC Therapeutics in APAC Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool’, which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8...
Table of Contents

1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Symptoms 10
2.2 Etiology 11
2.3 Pathophysiology 12
2.4 Co-morbidities and Complications 12
2.5 Diagnosis 13
2.5.1 Physical Examination 13
2.5.2 Sputum Cytology 13
2.5.3 Imaging Tests 13
2.5.4 Biopsy 14
2.6 Classification 15
2.6.1 Adenocarcinoma 15
2.6.2 Squamous Cell Carcinoma 15
2.6.3 Large Cell Carcinoma 15
2.7 Epidemiology 15
2.8 Prognosis and Disease Staging 16
2.8.1 Staging 16
2.9 Treatment Options 18
2.9.1 Surgery and Radiation Therapy 18
2.9.2 Pharmacological 18
2.9.3 Treatment Algorithms and Prescribing Habits 20

3 Marketed Products 23
3.1 Therapeutic Landscape 24
3.1.1 Alimta (pemetrexed disodium) – Eli Lilly and Company 24
3.1.2 Abraxane (nab-paclitaxel) – Celgene 26
3.1.3 Iressa (gefitinib) – AstraZeneca 28
3.1.4 Tarceva (erlotinib hydrochloride) – F. Hoffmann-La Roche 29
3.1.5 Xalkori (crizotinib) – Pfizer 31
3.1.6 Avastin (bevacizumab) – F. Hoffmann-La Roche 32
3.1.7 Gilotrif (afatinib) – Boehringer Ingelheim 34
3.2 Comparative Efficacy and Safety 34

4 Pipeline Products 37
4.1 Overall Pipeline 37
4.2 Pipeline Analysis by Molecule Type 39
4.3 Pipeline Analysis by Mechanism of Action 41
4.4 Clinical Trials 44
4.4.1 Failure Rate 44
4.4.2 Patient Enrollment and Clinical Trial Size 46
4.4.3 Duration 48
4.5 Promising Drug Candidates in the Pipeline 50
4.5.1 Ramucirumab (IMC-1121B) – Eli Lilly and Company 50
4.5.2 Necitumumab (IMC-11F8) – Eli Lilly and Company 50
4.5.3 Onartuzumab (MetMab) – F. Hoffmann-La Roche 51
4.5.4 Ganetespib (STA-9090) – Synta 52
4.5.5 Nintedanib (BIBF1120) – Boehringer Ingelheim 52
4.5.6 Dacomitinib (PF-00299804) – Pfizer 53
4.5.7 LDK378 – Novartis 54
4.5.8 Yervoy (ipilimumab) – Bristol-Myers Squibb 54
4.5.9 Nivolumab (BMS-936558/ONO-4538) – Bristol Myers Squibb 55

5 Market Forecast to 2019 56
5.1 Geographical Markets 56
5.1.1 APAC Market 56
5.1.2 India 57
5.1.3 Australia 60
5.1.4 China 62
5.1.5 Japan 64
5.2 Drivers and Barriers for the Disease Market 66
5.2.1 Drivers 66
5.2.2 Barriers 66

6 Deals and Strategic Consolidations 68
6.1 Major Co-development Deals 69
6.1.1 OxOnc Enters Co-development Agreement with Pfizer for Crizotinib 70
6.1.2 SFJ Pharma Enters Co-development Agreement with Pfizer for Dacomitinib 70
6.1.3 Merck Enters Co-development Agreement with Endocyte for Cancer Drug 71
6.1.4 Roche Enters Co-development Agreement with Clovis 71
6.1.5 Abbott Laboratories Enters Co-development Agreement with GlaxoSmithKline 71
6.2 Major Licensing Deals 71
6.2.1 Chugai Enters Licensing Agreement with Roche for Onartuzumab and Lebrikizumab 72
6.2.2 Azaya Enters Licensing Agreement with CANbridge Life Sciences for ATI-1123 73
6.2.3 Merck Expands Licensing Agreement with Biomira 73
6.2.4 Clovis Enters Licensing Agreement with Avila Therapeutics 73

7 Appendix 74
7.1 All Pipeline Drugs by Phase 74
7.1.1 Discovery 74
7.1.2 Preclinical 75
7.1.3 IND-filed 78
7.1.4 Phase I 78
7.1.5 Phase II 82
7.1.6 Phase III 86
7.1.7 Undisclosed 89
7.2 Market Forecasts to 2019 97
7.2.1 APAC 97
7.2.2 India 98
7.2.3 Australia 98
7.2.4 China 98
7.2.5 Japan 99
7.3 Market Definitions 99
7.4 Abbreviations 99
7.5 Bibliography 102
7.6 Research Methodology 105
7.6.1 Coverage 105
7.6.2 Secondary Research 106
7.6.3 Primary Research 106
7.6.4 Therapeutic Landscape 106
7.6.5 Geographical Landscape 108
7.6.6 Pipeline Analysis 109
7.7 Expert Panel Validation 109
7.8 Contact Us 109
7.9 Disclaimer 109

List of Tables

Table 1: Non-Small Cell Lung Cancer Market, Common Symptoms of Non-Small Cell Lung Cancer 11
Table 2: Non-Small Cell Lung Cancer Market, Risk Factors of Non-Small Cell Lung Cancer Market 12
Table 3: Non-Small Cell Lung Cancer Market, American Joint Committee on Cancer’s Tumor Node Metastasis Staging System, 2010 17
Table 4: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Discovery), 2013 74
Table 5: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Preclinical), 2013 75
Table 6: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (IND-filed), 2013 78
Table 7: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase I), 2013 78
Table 8: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase II), 2013 82
Table 9: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase III), 2013 86
Table 10: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013 89
Table 11: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Forecast, 2012–2019 97
Table 12: Non-Small Cell Lung Cancer Market, India, Market Forecast, 2012–2019 98
Table 13: Non-Small Cell Lung Cancer Market, Australia, Market Forecast, 2012–2019 98
Table 14: Non-Small Cell Lung Cancer Market, China, Market Forecast, 2012–2019 98
Table 15: Non-Small Cell Lung Cancer Market, Japan, Market Forecast, 2012–2019 99

List of Figures

Figure 1: Non-Small Cell Lung Cancer Market, Asia-Pacific, Distribution of Prevalence Population, 2012–2019 16
Figure 2: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013 20
Figure 3: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013 21
Figure 4: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Advanced Metastatic Tumors, 2013 22
Figure 5: Non-Small Cell Lung Cancer Market, Global, Annual Sales, 2012 24
Figure 6: Non-Small Cell Lung Cancer Market, Global, Alimta (pemetrexed disodium) Annual Sales ($bn), 2004–2012 25
Figure 7: Non-Small Cell Lung Cancer Market, Global, Abraxane (nab-paclitaxel) Annual Sales ($m), 2009–2012 27
Figure 8: Non-Small Cell Lung Cancer Market, Global, Iressa (gefitinib) Annual Sales ($m), 2005–2012 28
Figure 9: Non-Small Cell Lung Cancer Market, Global, Tarceva (erlotinib) Annual Sales ($bn), 2006–2012 30
Figure 10: Non-Small Cell Lung Cancer Market, Global, Xalkori (crizotinib) Annual Sales ($m), 2012–2013 31
Figure 11: Non-Small Cell Lung Cancer Market, Global, Avastin (bevacizumab) Annual Sales ($bn), 2006–2012 33
Figure 12: Non-Small Cell Lung Cancer Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 35
Figure 13: Non-Small Cell Lung Cancer Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2013 38
Figure 14: Non-Small Cell Lung Cancer Market, Global, Pipeline by Molecule Type and Stage of Development, 2013 40
Figure 15: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, 2013 42
Figure 16: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development (Number), 2013 43
Figure 17: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Failure Rate (%), 2013 45
Figure 18: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Size (Participants), 2013 47
Figure 19: Non-Small Cell Lung Cancer Market, Global, Pipeline Clinical Trial Duration (months), 2013 49
Figure 20: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Size, 2012–2019 57
Figure 21: Non-Small Cell Lung Cancer Market, India, Market Size, 2012–2019 59
Figure 22: Non-Small Cell Lung Cancer Market, Australia, Market Size, 2012–2019 61
Figure 23: Non-Small Cell Lung Cancer Market, China, Market Size, 2012–2019 63
Figure 24: Non-Small Cell Lung Cancer Market, Japan, Market Size, 2012–2019 65
Figure 25: Non-Small Cell Lung Cancer Market, Global Deals by Value, Year and Stage of Development, 2006–2013 68
Figure 26: Non-Small Cell Lung Cancer Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006–2013 69
Figure 27: Non-Small Cell Lung Cancer Market, Global, Co-development Deals by Geography, 2006–2013 70
Figure 28: Non-Small Cell Lung Cancer Market, Global, Licensing Deals by Geography, 2006–2013 72
Figure 29: GBI Research Market Forecasting Model (Example) 108

Upcoming Reports:

Hybrid Cars Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
The growing concern over the increasing carbon emissions has forced global automobile industry to develop advance and better vehicles running on alternative fuels. The factors such as Volatile Oil Prices, Shrinking of Fuel Reserves, Government Support and European Emission Standards are some of the factors driving the hybrid cars market. The report anticipates global hybrid automobile industry will witness a CAGR of more than 20 % over the period of 2012-2018. Government support will play a vital role in the growth of this industry.  This research report analyzes...
Fire Protection Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Increase in expenditure on the protection of assets from fire hazards is contributing to the growth of the fire protection equipment market. Moreover, increasing awareness in combating fire hazards along with considerable growth in building of infrastructures is also fueling this market. Therefore, this market has witness traction in the fields of the banking, retail, energy and power, healthcare, government, and mining among others. Organizations across the globe have remarkably increased their spending on fire protection to safeguard their infrastructure and also to reduce human losses....
Histology And Cytology Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020
By - Transparency Market Research
Histology and Cytology both come under the scientific medical specialty that is concerned with the diagnosis of diseases and other conditions. Histology is the study of human tissues, including structure and function whereas cytology is the study of human cells. The respective tests are performed by placing the stained tissue or cell sample under a light microscope or an electron microscope which will enable the scientists to study the sample’s microscopic anatomy. Histology and cytology market has experienced a huge growth with regards to healthcare industries as a number of fatal...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

India’s Auto Exports Register Record High Figures in 2014-15
May 21, 2015  
In the fiscal year 2014-15, Indian factories exported a record number of 3.5 million vehicles, which is 15% higher than what they managed a year back. However, domestic sales rose by only 5% since last financial year, with 2.6 million units being sold.  Exports of utility vehicles, commercial vehicles, cars and two- wheelers have increased every year since 2000. But domestic car...
Turkey’s Labor Dispute Affects Ford’s Production
May 21, 2015  
With the ongoing labor dispute in Turkey, Ford’s Turkish manufacturing facility has been hit. Ford Otosan, a joint venture between the company and Turkey’s Koc Holding, mentioned that due to supply problems, production has been temporary stalled at its plants located at Yenikoy and Golcuk in northwestern part of the country. Earlier this week, production at Tofas and Oyak Renault,...
International Automakers Slashing Prices in China
May 21, 2015  
With a slowing Chinese economy, the international automakers are cutting prices of vehicles to be sold in the nation. This has hit the profit margins of the automakers who are struggling with a slowdown in demand.  Last week saw Ford Motor Co. and General Motors slashing their prices on Chinese models. It closely follows rival Volkswagen AG’s move last month to offer...
Century Old Vancouver Sheet Metal Enterprise Shutters
May 21, 2015  
A Vancouver based metal works business in operation for almost 100 years, known for custom metal works shuttered this week.  The business known as Main Sheet Metal Works, a fabrication shop for sheet-metal on Main Street which is wedged between Pacific Central Station and Chinatown has existed for more than ninety years.  As commented by a third generation member of...
Plastic Pitches to Receive Fame in Protection of Artificial Turf
May 21, 2015  
Soccer is wary of several things. Foreign owners, players, and technology enthusiasts that do not agree to celebrate against an earlier team snoods, and particularly artificial turf fields. However, Major League Soccer (MLS) is suspicious of the latter most of the time. If asked anyone about North American soccer’s enemy, and it is undoubtedly a toss between plastic pitches and...